Loading...

APC/Cyanine7 anti-mouse/human CD45R/B220 Antibody

Pricing & Availability
Clone
RA3-6B2 (See other available formats)
Regulatory Status
RUO
Other Names
B220
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RA3-6B2_APCCy7_060308
C57BL/6 splenocytes stained with RA3-6B2 APC/Cyanine7
  • RA3-6B2_APCCy7_060308
    C57BL/6 splenocytes stained with RA3-6B2 APC/Cyanine7
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
103223 25 µg £61
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103224 100 µg £135
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45R, also known as B220, is an isoform of CD45. It is a member of the protein tyrosine phosphatase (PTP) family with a molecular weight of approximately 180-240 kD. CD45R is expressed on B cells (at all developmental stages from pro-B cells through mature B cells), activated B cells, and subsets of T and NK cells. CD45R (B220) is also expressed on a subset of abnormal T cells involved in the pathogenesis of systemic autoimmunity in MRL-Faslpr and MRL-Fasgld mice. It plays a critical role in TCR and BCR signaling. The primary ligands for CD45 are galectin-1, CD2, CD3, and CD4. CD45R is commonly used as a pan-B cell marker; however, CD19 may be more appropriate for B cell specificity.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse, Human
Reported Reactivity
Cat
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Abelson murine leukemia virus-induced pre-B tumor cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro and in vivo modulation of B cell responses2-4, immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections5,6, and spatial biology (IBEX)14,15.

Application References

(PubMed link indicates BioLegend citation)
  1. Coffman RL. 1982. Immunol. Rev. 69:5. (IP)
  2. George A, et al. 1994. J. Immunol. 152:1014. (Activ)
  3. Asensi V, et al. 1989. Immunology 68:204. (Activ)
  4. Domiati-Saad R, et al. 1993. J. Immunol. 151:5936. (Activ)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Monteith CE, et al. 1996. Can. J. Vet. Res. 60:193. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Chang C L-T, et al. 2007. J. Immunol. 178:6984.
  9. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  10. Lang GL, et al. 2008. Blood 111:2158. PubMed
  11. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  12. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  13. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  14. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  15. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Chuang H, et al. 2014. Nat Commun. 5:4602. PubMed
  2. Huang Y, et al. 2015. Proc Natl Acad Sci U S A. 112:39. PubMed
  3. Chung Y, et al. 2014. J Vis Exp. 89: 51660. PubMed
  4. Ishikura S, et al. 2016. J Biol Chem. 291: 15282 - 15291. PubMed
  5. Yu X, et al. 2020. Nat Commun. 11:1110. PubMed
  6. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  7. Lawson H, et al. 2021. Stem Cell Reports. 16:2784. PubMed
  8. Rivas MA, et al. 2021. Nat Immunol. 22:240. PubMed
  9. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  10. Van Deren DA, et al. 2022. Development. 149: . PubMed
  11. Omer-Javed A, et al. 2022. Cell. 185:2248. PubMed
  12. Tessaro FHG, et al. 2022. Cell Rep. 39:110977. PubMed
  13. Gupta S, et al. 2022. Sci Adv. 8:eabn4886. PubMed
  14. Xu Y, et al. 2023. EMBO Rep. 24:e55503. PubMed
  15. Kraemer AN, et al. 2022. Front Immunol. 13:933191. PubMed
  16. Urata S, et al. 2023. Microbiol Immunol. 67:105. PubMed
  17. Yang L, et al. 2023. Acta Pharmacol Sin. :. PubMed
  18. Kang J, et al. 2023. JCI Insight. 8: . PubMed
  19. Wu Y, et al. 2023. Adv Mater. 35:e2210787. PubMed
  20. Xu H, et al. 2023. Elife. 12:. PubMed
  21. Inaba A, et al. 2023. Nat Commun. 14:2071. PubMed
  22. Griffin GK, et al. 2023. Nature. 618:834. PubMed
  23. Lechuga-Vieco AV, et al. 2020. Sci Adv. 6:eaba5345. PubMed
  24. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
  25. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  26. Gazit R, et al. 2014. J Exp Med. 211:1315. PubMed
  27. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  28. Roco JA et al. 2019. Immunity. 51(2):337-350 . PubMed
  29. Sharma GP, et al. 2021. PLoS One. 16:e0259042. PubMed
  30. Stewart I et al. 2018. Immunity. 49(3):477-489 . PubMed
  31. Chen S, et al. 2022. Cancer Discov. :. PubMed
  32. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  33. Roufaiel M, et al. 2016. Nat Immunol. 10.1038/ni.3564. PubMed
  34. Jacoby E, et al. 2016. Blood. 127: 1361 - 1370. PubMed
  35. D'Auria K, et al. 2013. Infect Immun . 81:3814. PubMed
  36. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  37. Sun Y et al. 2018. Cancer cell. 34(4):643-658 . PubMed
  38. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
  39. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  40. Leimkühler NB, et al. 2020. Cell Stem Cell. 28:637. PubMed
  41. Palm A, et al. 2016. Sci Rep. 10.1038/srep20531. PubMed
  42. Fuster JJ, et al. 2020. Cell Rep. 33:108326. PubMed
  43. Mathew NR, et al. 2021. Cell Reports. 35(12):109286. PubMed
  44. Petursdottir D, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01699. PubMed
  45. Shinoda K, et al. 2020. Cell Reports. 29(13):4471-4481.e6.. PubMed
  46. Fujino T, et al. 2021. Nat Commun. 12:1826. PubMed
  47. Inoue D, et al. 2021. Nat Genet. 53:707. PubMed
  48. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  49. Zong L, et al. 2021. NPJ Aging Mech Dis. 7:25. PubMed
  50. Sochalska M, et al. 2016. Oncogene. 10.1038/onc.2016.362. PubMed
  51. Dema B, et al. 2014. J Exp Med. 211:2159. PubMed
  52. Thayer T, et al. 2011. Diabetes. 60:2144. PubMed
  53. Yoshimi A, et al. 2019. Nature. 574:273. PubMed
  54. Sarapulov AV, et al. 2020. Front Immunol. 11:599. PubMed
  55. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  56. Rogawski DS, et al. 2021. Nat Commun. 12:2792. PubMed
  57. Muppidi J, et al. 2015. J Exp Med. 212: 2213 - 2222. PubMed
  58. Dos Santos Dias L, et al. 2021. PLoS Pathog. e1009324:17. PubMed
  59. Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed
  60. Lam WY et al. 2018. Cell reports. 24(9):2479-2492 . PubMed
  61. He W et al. 2018. Immunity. 49(6):1175-1190 . PubMed
  62. Sato R, et al. 2020. Int Immunol. 499:32. PubMed
  63. Benet Z, et al. 2021. Cell Reports. 34(6):108733. PubMed
  64. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  65. Kleppe M et al. 2018. Cancer cell. 33(1):29-43 . PubMed
  66. Forbester JL, et al. 2020. J Virol. 94:. PubMed
  67. Soto-Díaz K, et al. 2021. Front Immunol. 12:734349. PubMed
  68. Rivas MA, et al. 2021. Front Immunol. 12:688493. PubMed
  69. Rodda L, et al. 2015. J Immunol. 195: 4781 - 4791. PubMed
  70. Venturutti L, et al. 2020. Cell. 182(2):297-316.e27. PubMed
  71. Yao M, et al. 2020. Cell. 180(3):502-520. PubMed
  72. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  73. Grune J, et al. 2022. Nat Cardiovasc Res. 1:649. PubMed
  74. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
  75. Zhang C, et al. 2020. Cell Rep. 32:108206. PubMed
  76. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  77. Sullivan JA, et al. 2020. Cell Rep. 30:1039. PubMed
  78. St Clair JB, et al. 2017. PLoS One. 12:e0170556. PubMed
  79. Roy K, et al. 2019. Immunity. 50:616. PubMed
  80. Bei T, et al. 2021. Molecules. 26:. PubMed
  81. Panea C, et al. 2021. Commun Biol. 4:913. PubMed
  82. Lim CX, et al. 2020. Cell Rep. 3793:30. PubMed
  83. Chauveau L, et al. 2021. EMBO Rep. 22:e52447. PubMed
  84. Jacoby E, et al. 2016. Nat Commun. 7:12320. PubMed
  85. He Z, et al. 2016. Exp Hematol. 44:161-165. PubMed
  86. Fournier M, Bijl C 2015. Stem Cells Dev. 24: 2413-2422. PubMed
  87. Gough D, et al. 2014. Blood. 124:2252. PubMed
  88. Wang YH, et al. 2019. Front Immunol. 10:1909. PubMed
  89. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  90. Yang S, et al. 2022. J Exp Med. 219:. PubMed
  91. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  92. Huang Y, et al. 2016. J Immunol. 196: 217 - 231. PubMed
  93. Georgoudaki A, et al. 2016. Cell Rep. 15: 2000-2011. PubMed
  94. DiToro D, et al. 2020. Immunity. 650:52. PubMed
  95. Nowlan B, et al. 2019. Haematologica. 105:71. PubMed
  96. Wang X, et al. 2021. EMBO J. 40:e105926. PubMed
  97. Yan-Feng L, et al. 2017. Sci Rep. 7:40133. PubMed
  98. Xiao G, et al. 2018. Cell. 173:470. PubMed
  99. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  100. Kim DK, et al. 2022. Nat Commun. 13:6292. PubMed
  101. Zhang CR, et al. 2022. Blood Cancer Discov. 3:220. PubMed
  102. Rive CM, et al. 2022. Mol Ther Methods Clin Dev. 26:4. PubMed
  103. King R, et al. 2021. Sci Adv. 7:eabj5293. PubMed
  104. Kobia FM, et al. 2020. PLoS Biol. 18:e3000850. PubMed
  105. Haniuda K, et al. 2020. Cell Rep. 33:108333. PubMed
  106. Kovacs SB, et al. 2021. STAR Protoc. 2:100244. PubMed
  107. Uribe-Herranz M, et al. 2018. JCI Insight. 3. PubMed
  108. Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
  109. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
  110. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  111. Cantor DJ et al. 2019. Cell reports. 26(1):108-118 . PubMed
  112. Kim SK, et al. 2018. Genes Dev. 32:849. PubMed
  113. Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed
  114. Katzmarski N, et al. 2021. Nat Immunol. 22:1382. PubMed
  115. Lee HY, et al. 2021. Curr Protoc. 1:e272. PubMed
  116. Baptista M, et al. 2016. Nat Commun. 7:12175. PubMed
  117. Aryal B, et al. 2016. Nat Commun. 7:12313. PubMed
  118. Andresen L, et al. 2016. PLoS One. 11: 0148428. PubMed
  119. Altin J, et al. 2014. Proc Natl Acad Sci U S A. 111:2067. PubMed
  120. Luo H, et al. 2019. Cell Rep. 26:945. PubMed
  121. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
  122. Jaeger N, et al. 2020. Cell Rep. 33:108331. PubMed
  123. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  124. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
  125. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
  126. BJ L, et al. 2017. J Exp Med . 10.1084/jem.20161461. PubMed
  127. Sato-Hashimoto M, et al. 2011. J Immunol. 187:291. PubMed
  128. Whiteley AM et al. 2017. eLife. 6 pii: e26435. PubMed
  129. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
RRID
AB_313006 (BioLegend Cat. No. 103223)
AB_313006 (BioLegend Cat. No. 103224)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

B cells, T cell subset, NK cell subset

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
B cells, NK cells, T cells
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID 5788 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD45R
Specificity Alt (DOES NOT SHOW ON TDS):
CD45R/B220
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD45R on UniProt.org

Other Formats

View All CD45R/B220 Reagents Request Custom Conjugation
Description Clone Applications
Alexa Fluor® 594 anti-mouse/human CD45R/B220 RA3-6B2 IHC-F,FC,3D IHC
APC anti-mouse/human CD45R/B220 RA3-6B2 FC
Biotin anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F
FITC anti-mouse/human CD45R/B220 RA3-6B2 FC
PE anti-mouse/human CD45R/B220 RA3-6B2 FC
PE/Cyanine5 anti-mouse/human CD45R/B220 RA3-6B2 FC
Purified anti-mouse/human CD45R/B220 RA3-6B2 FC,CyTOF®,IHC-F,IHC-P,IP,Activ
PE/Cyanine7 anti-mouse/human CD45R/B220 RA3-6B2 FC
APC/Cyanine7 anti-mouse/human CD45R/B220 RA3-6B2 FC
Alexa Fluor® 488 anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F,3D IHC
Alexa Fluor® 647 anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Alexa Fluor® 700 anti-mouse/human CD45R/B220 RA3-6B2 FC
PerCP anti-mouse/human CD45R/B220 RA3-6B2 FC
PerCP/Cyanine5.5 anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 421™ anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F
Brilliant Violet 570™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 650™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 605™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 785™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 510™ anti-mouse/human CD45R/B220 RA3-6B2 FC,IHC-F,SB
Purified anti-mouse/human CD45R/B220 (Maxpar® Ready) RA3-6B2 FC,CyTOF®
Brilliant Violet 711™ anti-mouse/human CD45R/B220 RA3-6B2 FC
PE/Dazzle™ 594 anti-mouse/human CD45R/B220 RA3-6B2 FC
APC/Fire™ 750 anti-mouse/human CD45R/B220 RA3-6B2 FC
Brilliant Violet 750™ anti-mouse/human CD45R/B220 RA3-6B2 FC
TotalSeq™-A0103 anti-mouse/human CD45R/B220 RA3-6B2 PG
Spark Blue™ 550 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark NIR™ 685 anti-mouse/human CD45R/B220 RA3-6B2 FC
TotalSeq™-B0103 anti-mouse/human CD45R/B220 RA3-6B2 PG
Ultra-LEAF™ Purified anti-mouse/human CD45R/B220 RA3-6B2 FC,CyTOF®,IHC-F,IHC-P,IP,Activ
TotalSeq™-C0103 anti-mouse/human CD45R/B220 RA3-6B2 PG
PE/Fire™ 640 anti-mouse/human CD45R/B220 RA3-6B2 FC
APC/Fire™ 810 anti-mouse/human CD45R/B220 RA3-6B2 FC
PE/Fire™ 700 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark Violet™ 538 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark YG™ 581 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark YG™ 570 anti-mouse/human CD45R/B220 RA3-6B2 IHC-F
PE/Fire™ 810 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark Blue™ 574 anti-mouse/human CD45R/B220 Antibody RA3-6B2 FC
Spark Violet™ 423 anti-mouse/human CD45R/B220 Antibody RA3-6B2 FC
Spark Red™ 718 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark UV™ 387 anti-mouse/human CD45R/B220 RA3-6B2 FC
Spark PLUS UV395™ anti-mouse/human CD45R/B220 RA3-6B2 FC
Go To Top Version: 3    Revision Date: 04/25/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account